Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 8/20 | 0.32 |
| ▸ | ATR | Q13535 | 6/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.32 |
| ▸ | MTOR | P42345 | 6/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128998 | 0.97 | MET (0.35) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL20128952 | 0.97 | MET (0.35) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL20128931 | 0.97 | MET (0.35) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL20129271 | 0.96 | MET (0.33) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL20129060 | 0.95 | MET (0.34) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL27097846 | 0.89 | MET (0.32) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL20233608 | 0.89 | MET (0.32) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL20128980 | 0.89 | FAAH (0.36) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL20129182 | 0.88 | MET (0.31) | KDM4CMETL3MBTL1NPC1RAB9A | |
| SCHEMBL20133377 | 0.86 | FAAH (0.40) | NPC1RAB9AATMATRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | KDM4C 2111/4885MET 281/4885L3MBTL1 1412/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | KDM4C 1589/4885MET 557/4885L3MBTL1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.